EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies

Rawan G Faramand, Zhuoer Xie, Michael D Jain iD

Journal of Clinical Oncology · 10.03.2026 · 44 (8) · 698-708

DOI: 10.1200/jco-25-02087 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2026. Verfasst von Rawan G Faramand und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials and real-world evidence have established the benefit of chimeric antigen receptor (CAR) T-cell therapy to reduce progression of hematologic malignancies and, in some settings, increase overall survival. However, recent studies have highlighted that patients in long-term remission remain at risk of morbidity and nonrelapse mortality, primarily because of infections and subsequent myeloid malignancies. In addition, these patients may also be survivors of chemotherapy, radiation, and/or stem-cell transplant, with broad survivorship needs. Here, we provide a roadmap for the care of patients in long-term remission after CAR-T-cell therapies and discuss avenues for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumans

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

ORCID-Profile: Michael D Jain

Zitieren

APA

Faramand, R. G., Xie, Z., & Jain, M. D. (2026). Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. Journal of Clinical Oncology, 44(8), 698-708. https://doi.org/10.1200/jco-25-02087

Vancouver

Faramand RG, Xie Z, Jain MD. Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. Journal of Clinical Oncology. 2026;44(8):698-708. doi:10.1200/jco-25-02087

BibTeX
@article{Faramand2026,
  author = {Faramand, Rawan G and Xie, Zhuoer and Jain, Michael D},
  title = {Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {8},
  pages = {698--708},
  doi = {10.1200/jco-25-02087}
}
Kostenlos starten →